A MedUni Vienna-led study on AC102 shows promise for treating acute sudden hearing loss by protecting inner ear structures and reducing inflammation. Phase I safety trials are successful, and Phase II efficacy trials are underway. If effective, AC102 could be an alternative to cortisone.